SCHEDULE: FMR LLC Reports 8.8% Stake in Trevi Therapeutics

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 8.8% of Trevi Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Trevi Therapeutics Inc. common stock.
• As of June 30, 2026, the aggregate amount beneficially owned is 12,562,839.08 shares.
• This represents 8.8% of the class of securities.
• FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is classified as an investment adviser (IA).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new operational or financial disclosures.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, which can indicate confidence in the company's long-term prospects.

Negatives

• No new financial or operational information is provided in this filing, limiting insights into the company's current performance.

Risks

• The filing does not detail the specific reasons for acquiring this stake, leaving potential strategic intentions unclear.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Trevi Therapeutics Inc.'s future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. The presence of FMR LLC, a major financial services company, suggests a potentially positive view of Trevi Therapeutics' market position or future growth, though the specific investment thesis is not disclosed.

Stakeholder Impact

• Shareholders may view the increased institutional ownership by FMR LLC and Abigail P. Johnson as a positive signal, potentially increasing investor confidence.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their beneficial ownership of Trevi Therapeutics Inc. common stock.

Key Dates

Keywords

Trevi Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock